Radiopharmaceutical firm Cytogen has cut staff at its AxCell Biosciences unit by 75% in what the company said was a sign of its continuing emphasis on oncology products. The move is expected to lower Cytogen’s annual operating expenses by about $1.4 million, starting in the fourth quarter of 2002.
By AuntMinnie.com staff writersSeptember 17, 2002
Related Reading
Cytogen warned by Nasdaq, August 15, 2002
Cytogen revenues climb in Q2, August 1, 2002
ProstaScint being tested as IMRT guide, June 6, 2002
Cytogen raises $5 million, June 5, 2002
Cytogen brings BrachySeed Pd-103 to U.S., May 30, 2002
Copyright © 2002 AuntMinnie.com